Nes-Ziona, Israel, April 3,2019 – Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the H.C. Wainwright Global Life Sciences 2019 conference being held at the Grosvenor House in London, U.K. The presentation is scheduled for April 8th 2019 at 9:10am London Time.
Allocetra™ by Enlivex was designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as “unmet medical needs”, including prevention or treatment of complications associated with bone marrow transplantations (BMT) and/or hematopoietic stem cell transplantations (HSCT); organ dysfunction and acute multiple organ failure associated with Sepsis; and enablement of an effective treatment of solid tumors via immune checkpoint rebalancing. For more information about the H.C. Wainwright Global Life Sciences 2019 conference, visit www.hcwevents.com.
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visit http://www.enlivex.com.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.